Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management
Authors
Keywords
-
Journal
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
Volume -, Issue 41, Pages e182-e189
Publisher
American Society of Clinical Oncology (ASCO)
Online
2021-06-02
DOI
10.1200/edbk_323835
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
- (2021) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma
- (2020) Praful Ravi et al. JAMA Oncology
- Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors
- (2020) Denis Maillet et al. EUROPEAN JOURNAL OF CANCER
- Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma
- (2020) Bradley A. McGregor et al. EUROPEAN JOURNAL OF CANCER
- Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
- (2020) Roberto Iacovelli et al. Targeted Oncology
- Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors
- (2020) Keitaro Shimozaki et al. Cancer Management and Research
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Second-line tyrosine kinase inhibitor-therapy after immunotherapy-failure
- (2020) Marina Deuker et al. Current Opinion in Supportive and Palliative Care
- Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)
- (2020) Rana R. McKay et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
- (2019) Y Fradet et al. ANNALS OF ONCOLOGY
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA57Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC)
- (2019) M-O Grimm et al. ANNALS OF ONCOLOGY
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
- (2018) Caroline Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
- (2018) Dylan J. Martini et al. Cancer Immunology Research
- Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
- (2018) Thomas Powles et al. BRITISH JOURNAL OF CANCER
- 871PKEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)
- (2018) F Donskov et al. ANNALS OF ONCOLOGY
- Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
- (2018) Marie-Léa Gauci et al. CLINICAL CANCER RESEARCH
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now